The room stood and yelled for 42 seconds at a pancreatic-cancer drug

On May 31 in Chicago, a doctor named Brian Wolpin stood at the podium of the ASCO conference, the largest cancer meeting in the world. He clicked to a slide showing a survival curve. The auditorium broke into cheers and whistles that did not stop for 42 full seconds. Wolpin had to fill the time at the podium. "That time was not built into my talk."

The drug on the slide is called daraxonrasib. It is a pill. It targets a protein called RAS, which is mutated in more than 90% of pancreatic tumors. For forty years no drug could touch RAS. Pancreatic cancer remained one of the hardest cancers in medicine.

In the new trial, patients took the pill after their first treatment had failed. They lived a median of 13.2 months. Patients without it lived 6.6. The drug doubled the time they had left.

Six and a half extra months. That is what the room was yelling at.

Now the verse.

The book of Joel was written in the aftermath of a locust plague in ancient Judah. Swarms had come in waves and eaten the country bare. Crops gone, vineyards gone, even the temple sacrifices halted because there was no flour and no oil. An entire year of life eaten in a single season.

Into that wreckage, God speaks one line through the prophet Joel:

"I will restore to you the years that the swarming locust has eaten."

Read that line slowly. The promise is about the years. The time itself. The stretch of life the locusts had taken.

Pancreatic cancer has been a locust. For decades it has eaten the years patients still had ahead of them. On May 31, in a room full of doctors trained to keep a tight lid on hope, science handed back six and a half of those eaten months from a swarm that had taken them at will.

The yelling in that room was the sound of a verse coming true.